|
|
Articles
by
Andrew J. Saykin |
Total Records (
3 ) for
Andrew J. Saykin |
|
 |
|
|
|
Paul S. Aisen
,
Ronald C. Petersen
,
Michael C. Donohue
,
Anthony Gamst
,
Rema Raman
,
Ronald G. Thomas
,
Sarah Walter
,
John Q. Trojanowski
,
Leslie M. Shaw
,
Laurel A. Beckett
,
Clifford R. Jack Jr.
,
William Jagust
,
Arthur W. Toga
,
Andrew J. Saykin
,
John C. Morris
,
Robert C. Green
and
Michael W. Weiner
|
|
The Clinical Core of the Alzheimers Disease Neuroimaging Initiative (ADNI) has provided clinical, operational, and data management support to ADNI since its inception. This article reviews the activities and accomplishments of the core in support of ADNI aims. These include the enrollment and follow-up of more than 800 subjects in the three original cohorts: healthy controls, amnestic mild cognitive impairment (now referred to as late MCI, or LMCI), and mild Alzheimers disease (AD) in the first phase of ADNI (ADNI 1), with baseline longitudinal, clinical, and cognitive assessments. These data, when combined with genetic, neuroimaging, and cerebrospinal fluid measures, have provided important insights into the neurobiology of the AD spectrum. Furthermore, these data have facilitated the development of novel clinical trial designs. ADNI has recently been extended with funding from an NIH Grand Opportunities (GO) award, and the new ADNI GO phase has been launched; this includes the enrollment of a new cohort, called early MCI, with milder episodic memory impairment than the LMCI group. An application for a further 5 years of ADNI funding (ADNI 2) was recently submitted. This funding would support ongoing follow-up of the original ADNI 1 and ADNI GO cohorts, as well as additional recruitment into all categories. The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations. |
|
|
|
|
Michael W. Weiner
,
Paul S. Aisen
,
Clifford R. Jack Jr.
,
William J. Jagust
,
John Q. Trojanowski
,
Leslie Shaw
,
Andrew J. Saykin
,
John C. Morris
,
Nigel Cairns
,
Laurel A. Beckett
,
Arthur Toga
,
Robert Green
,
Sarah Walter
,
Holly Soares
,
Peter Snyder
,
Eric Siemers
,
William Potter
,
Patricia E. Cole
and
Mark Schmidt
|
|
The Alzheimers Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimers disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C-11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid β (Aβ) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C-11 Pittsburgh compound B PET, and CSF measurements of Aβ and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD. |
|
|
|
|
Andrew J. Saykin
,
Li Shen
,
Tatiana M. Foroud
,
Steven G. Potkin
,
Shanker Swaminathan
,
Sungeun Kim
,
Shannon L. Risacher
,
Kwangsik Nho
,
Matthew J. Huentelman
,
David W. Craig
,
Paul M. Thompson
,
Jason L. Stein
,
Jason H. Moore
,
Lindsay A. Farrer
,
Robert C. Green
,
Lars Bertram
,
Clifford R. Jack Jr.
and
Michael W. Weiner
|
|
The role of the Alzheimers Disease Neuroimaging Initiative Genetics Core is to facilitate the investigation of genetic influences on disease onset and trajectory as reflected in structural, functional, and molecular imaging changes; fluid biomarkers; and cognitive status. Major goals include (1) blood sample processing, genotyping, and dissemination, (2) genome-wide association studies (GWAS) of longitudinal phenotypic data, and (3) providing a central resource, point of contact and planning group for genetics within the Alzheimers Disease Neuroimaging Initiative. Genome-wide array data have been publicly released and updated, and several neuroimaging GWAS have recently been reported examining baseline magnetic resonance imaging measures as quantitative phenotypes. Other preliminary investigations include copy number variation in mild cognitive impairment and Alzheimers disease and GWAS of baseline cerebrospinal fluid biomarkers and longitudinal changes on magnetic resonance imaging. Blood collection for RNA studies is a new direction. Genetic studies of longitudinal phenotypes hold promise for elucidating disease mechanisms and risk, development of therapeutic strategies, and refining selection criteria for clinical trials. |
|
|
|
|
|
|